Autoimmune diabetes

June 29, 2019

Partial or Sleeve gastrectomy functions as a curative therapy for autoimmune (Type I) diabetes (TIDM):  Partial/Sleeve gastrectomy promotes the expression of PD-L1, attenuates the expression of tumor suppressor TXNIP, augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 30/June/2019, 12.43 am

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical […]
June 27, 2019

Curing autoimmune diabetes  (TIDM) with HDAC (Histone deacetylase) inhibitors: Vorinostat-based therapy for autoimmune diabetes: Vorinostat (brand name: Zolinza and others), a histone deacetylase inhibitor used to treat cutaneous T-cell lymphoma (CTCL), increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 27/June/2019, 11.54 pm

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and […]
June 18, 2019

Ciliary neurotrophic factor (CNTF)-based curative therapy for autoimmune diabetes (TIDM):  Ciliary neurotrophic factor (CNTF)  increases the expression of PD-L1, decreases the expression of TXNIP, augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 18/June/2019, 10.56 pm

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical […]
June 12, 2019

Hydrogen sulphide (H2S)-based curative therapy for autoimmune diabetes (TIDM):  Hydrogen sulphide (H2S)  increases the expression of PD-L1, decreases the expression of TXNIP, augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 13/June/2019, 12.54 am

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical […]